Literature DB >> 24008431

Outcomes of choroidal melanomas treated with eye physics: a 20-year review.

Jesse L Berry1, Savita V Dandapani, Marta Stevanovic, Thomas C Lee, Melvin Astrahan, A Linn Murphree, Jonathan W Kim.   

Abstract

IMPORTANCE: The University of Southern California Eye Physics plaques compare favorably with the Collaborative Ocular Melanoma Study plaques in terms of late adverse effects from radiation, metastasis, and local tumor recurrence.
OBJECTIVE: To review the University of Southern California experience using Eye Physics plaques and Plaque Simulator software to treat choroidal melanomas and compare the outcomes with published results of the Collaborative Ocular Melanoma Study. DESIGN, SETTING, AND PARTICIPANTS: A retrospective case series of 82 patients treated for medium-sized choroidal melanoma from January 1, 1990, through December 30, 2010, using iodine 125 plaques and treatment simulation software developed at the University of Southern California. The dosimetric goal was 85 Gy in 7 days to a conformal volume enclosing the apex and a 2-mm margin surrounding the tumor base. Plaque localization was guided by the Plaque Simulator computer modeling system using preoperative imaging studies. MAIN OUTCOMES AND MEASURES: Primary outcome measures were local tumor control, globe preservation, and metastases. Secondary outcome measures were late radiation adverse effects including postoperative vision changes, optic neuropathy, radiation retinopathy, and cataract.
RESULTS: The median follow-up for 82 patients was 46.8 months (range, 1-171 months). Globe preservation was achieved in 80 patients (97.6%); 2 patients underwent enucleation for local recurrence. Metastatic disease developed in 9 patients (11.0%). Retinopathy was seen in 31 patients (37.8%), optic neuropathy in 12 (14.6%), and cataracts in 26 (31.7%). Postoperatively, 21 patients (25.6%) lost more than 6 lines of Snellen visual acuity. CONCLUSIONS AND RELEVANCE: When considering rates of local recurrence, metastases, and late radiation adverse effects, the University of Southern California results for medium-sized choroidal melanomas using Eye Physics plaques compared favorably with Collaborative Ocular Melanoma Study data. The Plaque Simulator 3-dimensional tumor-modeling program developed at the University of Southern California is a reliable method for determining plaque positioning preoperatively and for treating this cohort of patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24008431     DOI: 10.1001/jamaophthalmol.2013.4422

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  16 in total

1.  Optic Disc Dose Comparison Between 125I and 103Pd Collaborative Ocular Melanoma Study (COMS) Plaques Based on Current Clinical Practice.

Authors:  Yongsook C Lee; Shih-Chi Lin; Yongbok Kim
Journal:  Cureus       Date:  2021-06-28

2.  Transscleral resection without hypotensive anaesthesia vs iodine-125 plaque brachytherapy in the treatment of choroidal melanoma.

Authors:  J M Caminal; N Padrón-Pérez; L Arias; C Masuet-Aumatell; C Gutiérrez; J M Piulats; J Pera; J Català; M J Rubio; J Arruga
Journal:  Eye (Lond)       Date:  2016-04-01       Impact factor: 3.775

Review 3.  Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic Review of Radiation Dose.

Authors:  Jose J Echegaray; Nikolaos E Bechrakis; Nakul Singh; Claudine Bellerive; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2017-02-08

4.  Intraocular Dissemination of Uveal Melanoma Cells Following Radiotherapy: Evolving Management Over the Past Decade.

Authors:  Manuel Paez-Escamilla; Scott D Walter; Amir Mohsenin; Christina L Decatur; George J Harocopos; Sander Dubovy; J William Harbour
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2019-09-01       Impact factor: 1.300

5.  Long-term visual acuity outcomes in patients with uveal melanoma treated with 125I episcleral OSU-Nag plaque brachytherapy.

Authors:  C Ellis Wisely; Mersiha Hadziahmetovic; Rachel E Reem; Erinn M Hade; Subir Nag; Frederick H Davidorf; Douglas Martin; Colleen M Cebulla
Journal:  Brachytherapy       Date:  2016 Jan-Feb       Impact factor: 2.362

6.  Clinical evaluation of a paper chart for predicting ruthenium plaque placement in relation to choroidal melanoma.

Authors:  I Rospond-Kubiak; J Kociecki; B Damato
Journal:  Eye (Lond)       Date:  2017-09-29       Impact factor: 3.775

7.  Quantifying Subclinical and Longitudinal Microvascular Changes Following Episcleral Plaque Brachytherapy Using Spectral Domain-Optical Coherence Tomography Angiography.

Authors:  Kyle M Green; Brian C Toy; Bright S Ashimatey; Debarshi Mustafi; Richard L Jennelle; Melvin A Astrahan; Zhongdi Chu; Ruikang K Wang; Jonathan Kim; Jesse L Berry; Amir H Kashani
Journal:  J Vitreoretin Dis       Date:  2020-08-13

8.  Clinical Outcomes of Proton Beam Therapy for Choroidal Melanoma at a Single Institute in Korea.

Authors:  Tae Wan Kim; Euncheol Choi; Jeonghoon Park; Dong-Ho Shin; Su Kyung Jung; Susie Seok; Kwan Ho Cho; Joo-Young Kim; Dae Yong Kim; Tae Hyun Kim; Yang Kwon Suh; Yeon Joo Kim; Sung Ho Moon
Journal:  Cancer Res Treat       Date:  2017-04-19       Impact factor: 4.679

9.  Late Apical Recurrence of Choroidal Melanoma 10 Years after Successful Treatment with Brachytherapy.

Authors:  Grace C Shih; Bao Han A Le; Zelia M Correa; Maria E Sibug-Saber; Jonathan W Kim; Jesse L Berry
Journal:  Ocul Oncol Pathol       Date:  2017-12-22

10.  Outpatient ocular brachytherapy: The USC Experience.

Authors:  Sarah Joh; Mary E Kim; Michael Reilly; Sue Y Zhou; Jonathan Kim; Richard L Jennelle; Jesse L Berry
Journal:  Adv Radiat Oncol       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.